GQG Partners’s Ascendis Pharma A/S ASND Stock Holding History

GQG Partners’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,751	Closed	-$438K	–	82
2021 Q3	$438K	Buy	+2,751	New	+$376K	﹤0.01%	74

Other funds holding ASND

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

GQG Partners's ASND Position: Q4 2021 in Review

GQG Partners sold out of Ascendis Pharma A/S (ASND) in Q4 2021, closing a stake of 2,751 shares — an estimated $438K sold.

GQG Partners first reported a position in ASND in Q3 2021 and held it in 1 quarter. The position peaked at $438K in Q3 2021. 171 funds tracked by Wall St. Rank hold ASND as of Q4 2021.

GQG Partners reported no remaining Ascendis Pharma A/S position as of Q4 2021 after selling out during the quarter.
GQG Partners sold 2,751 Ascendis Pharma A/S shares in Q4 2021, an estimated $438K.
GQG Partners first reported a position in Ascendis Pharma A/S in Q3 2021 and held it in 1 quarter.
GQG Partners's Ascendis Pharma A/S position peaked at $438K in Q3 2021.
171 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2021.

Based on GQG Partners's 13F filing for Q4 2021, filed 14 Feb 2022.